Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b open-label study of BNT162b2 in immunocompromised participants ≥2 years of age
2021-001290-23Phase 2
- Sponsor
- BioNTech SE
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by BioNTech SE. Primary endpoints: Primary immunogenicity endpoints in evaluable participants without prior SARS-CoV-2 infection and Safety and tolerability endpoints.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-001290-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001290-23.